Cynata Therapeutics (CYYNF) News Today $0.19 0.00 (0.00%) (As of 12/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisChart All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Cynata Therapeutics Raises $8.1M After Positive Trial ResultsDecember 5, 2024 | tipranks.comCynata’s CYP-006TK Shows Promise in Diabetic Foot Ulcer TrialDecember 4, 2024 | tipranks.comCynata Therapeutics Requests ASX Trading HaltDecember 3, 2024 | tipranks.comCynata Therapeutics’ AGM Approves Key ResolutionsNovember 19, 2024 | markets.businessinsider.comCynata Therapeutics Announces New Share QuotationNovember 9, 2024 | markets.businessinsider.comAlive and Kicking: Watch this space on controversy-free stem-cell therapy trials, says CynataSeptember 5, 2024 | msn.comCynata Therapeutics Limited (CYYNF)August 29, 2024 | au.finance.yahoo.comCynata Therapeutics treats first patient in aGvHD drug trialMarch 6, 2024 | msn.comFirst Patient Treated in Phase 2 GvHD TrialMarch 4, 2024 | finance.yahoo.comVYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 14, 2023 | markets.businessinsider.comJefferies Reaffirms Their Buy Rating on C4 Therapeutics (CCCC)August 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: CymaBay Therapeutics (CBAY) and Vor Biopharma (VOR)August 11, 2023 | markets.businessinsider.comTScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 10, 2023 | technews.tmcnet.comCyteir Therapeutics 10% Owner Sold $106K In Company StockJuly 19, 2023 | benzinga.comDimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior AdvisorMay 2, 2023 | finance.yahoo.comWe Think Shareholders Are Less Likely To Approve A Pay Rise For Cynata Therapeutics Limited's (ASX:CYP) CEO For NowNovember 16, 2022 | finance.yahoo.comLUMC to Fund New Clinical Trial of Cynata's Cymerus™ MSCs in Kidney TransplantationNovember 4, 2022 | finance.yahoo.comCynata Therapeutics Stock (OTC:CYYNF), Earnings Estimates, EPS, and RevenueSeptember 26, 2022 | benzinga.comUS FDA Clears IND for Cynata's Phase 2 Clinical Trial of CYP-001 in GvHDMay 26, 2022 | finance.yahoo.comWe Think Cynata Therapeutics (ASX:CYP) Can Afford To Drive Business GrowthJanuary 14, 2022 | finance.yahoo.comHere’s why the Cynata (ASX:CYP) share price is rising todayDecember 29, 2021 | msn.comCynata Enters into a New Strategic Partnership with FujifilmSeptember 30, 2021 | finance.yahoo.com Get Cynata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYYNF and its competitors with MarketBeat's FREE daily newsletter. Email Address The #1 Coin for November 2024 (Ad)Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… You can get access to the report by clicking here now… CYYNF Media Mentions By Week CYYNF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CYYNF News Sentiment▼0.000.60▲Average Medical News Sentiment CYYNF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CYYNF Articles This Week▼00▲CYYNF Articles Average Week Get Cynata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYYNF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TGIFF News Today FFNTF News Today ABSCF News Today ACONW News Today ACRDF News Today ACRHF News Today ABMT News Today AGNPF News Today ALBHF News Today AKBLF News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:CYYNF) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cynata Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Cynata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
